



For more information contact:  
Jean Golden/612-385-2324  
PR@v2r.com

## **V2R Group Portfolio Company Clavina Diagnostics Files Second Patent Application for Suite of Revolutionary Blood Typing and Cross-Matching Technologies**

*Clavina Diagnostics builds patent fencing strategy around its suite of breakthrough technologies targeted at blood typing and cross matching.*

**ORLANDO, FL (APRIL 23, 2007)** – V2R Group, Inc., a leading high-technology commercialization & management company, announced today that portfolio company Clavina Diagnostics has begun to execute on its patent fencing strategy to commercialize its suite of initial technologies, with the filing of its second patent application in less than a month.

Clavina Diagnostics is a medical device company that will provide real-time, safe, reliable, and cost effective mechanisms for bodily fluid analysis, with blood-typing and cross-matching identified as the first applications. The company is building a unique position in the medical diagnostics market by optimizing a suite of proven methods for blood typing with advances in technology developed in Clavina's laboratories. Clavina's initial product offerings are advancements of the Manual Polybrene Test, a robust and simple blood-typing method which was originally developed by Dr. Parviz Lalezari, Clavina Diagnostics' Chief Life Science and Medical Advisor.

Clavina filed its initial patent application for modifications to the Manual Polybrene Test in early April 2007 and follows with its second patent application less than three weeks later. The second patent application covers yet another value-add modification to standard blood typing and cross-matching test protocols. In initial tests, this modification has been shown to produce significantly greater test performance in less than half the time of standard blood cross-matching tests. This advancement complements Clavina's initial blood analysis technology and begins to build a suite of blood typing methodologies and technologies which can be tailored to time critical situations such as accidents and military applications.

V2R Group CEO and Chairman Bahram Yusefzadeh commented, "The filing of this second patent application in less than a month is testament to the hard work of Clavina's team and positions the company for commercialization of a robust suite of blood typing and cross-matching technologies. We're especially pleased that this modification is substantially different than the technology of the first patent application and the combination will allow the company to provide a tailored solution to meet a myriad of applications."

-more-

**About Clavina Diagnostics**

Clavina Diagnostics is a medical device company that provides real-time, safe, reliable, and cost effective mechanisms for bodily fluid analysis, with blood-typing and cross-matching identified as the first applications. The company is currently focused on the development of a rapid and sensitive method for typing and cross-matching blood for transfusion with greater performance than currently available methods and applications ranging from first to third world. For more information, visit [www.clavina.com](http://www.clavina.com).

**About V2R Group, Inc.**

V2R Group is a leading company focused on the commercialization and management of highly innovative technologies. A key element of the V2R business model is to partner with universities to facilitate the transfer and commercialization of revolutionary technologies, with a focus on mid-stage high-tech businesses that have been developed past the initial research and development stage. V2R is led by a management team with many years of experience in technology commercialization and business. For more information, visit [www.v2r.com](http://www.v2r.com).

###

Note to Editors: Please contact Jean Golden/Public Relations Representative at 612.385.2324 or [PR@v2r.com](mailto:PR@v2r.com) for interview requests, photography and all other media requests.